Patients enrolled in a phase III trial for aneamia treatment in CKD patient that could lead to the removal of the need for multiple injections - Astellas Pharma Europe Ltd.
The first EU patients have been enrolled in the ALPINE study programme to test the safety and efficacy of roxadustat (ASP1517/FG-4592) as a potential new treatment for anaemia in patients with chronic kidney diseases (CKD). The campaign will total ~1800 people and is being separated into three european arms; ALPS, DOLOMITES, and PYRENEES, each encompassing both dialysis and non-dialysis patients. Studies will compare roxadustat with current treatments and placebo.
Roxadustat is the first drug to enter phase III in a potential new class of therapeutic compounds known as hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors (or HIF-PHIs). These compounds work by mimicking the affects of high altitude on the body, leading to raised Hb levels.
The treatment of anaemia in people with CKD has the potential to be changed dramatically, should the results of this phase III trial prove positive. Previously people with CKD have required two injections to treat their anaemia, this requires a lot of time, monitoring, testing and patient visits. Roxadustat will potentially allow this to be changed to one oral tablet, and potentially transfer management of this condition from secondary to primary care.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins